Anaveon AG
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.anaveon.com
Clinical Trials
7
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase I/II study of ANV600 single agent or in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)
- Conditions
- Advanced solid tumours
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Anaveon AG
- Target Recruit Count
- 194
- Registration Number
- 2023-509633-39-00
- Locations
- 🇳🇱
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam, Netherlands
🇫🇷Institut Universitaire Du Cancer Toulouse-Oncopole, Toulouse Cedex 9, France
🇫🇷Centre Hospitalier Regional De Marseille, Marseille, France
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
- Conditions
- Refractory Multiple MyelomaMultiple MyelomaAdult DiseaseRelapsed CancerHematologic Diseases
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Anaveon AG
- Target Recruit Count
- 4
- Registration Number
- NCT05641324
- Locations
- 🇩🇰
Vejle Hospital, Vejle, Denmark
🇫🇷Institut Paoli-Calmettes, Marseille, France
🇫🇷CHU de Nantes - Hôtel-Dieu, Nantes, France
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
- Conditions
- Melanoma (Skin)Cutaneous MelanomaAdult DiseaseAdvanced Solid TumorMetastatic Melanoma
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- Anaveon AG
- Target Recruit Count
- 29
- Registration Number
- NCT05578872
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
- Conditions
- Advanced Solid TumorAdult DiseaseLung Cancer
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Anaveon AG
- Target Recruit Count
- 55
- Registration Number
- NCT04855929
- Locations
- 🇪🇸
Hospital Vall d'Hebrón, Barcelona, Spain
🇪🇸START Madrid, Hospital Universitario HM Sanchinarro, Madrid, Spain
🇨🇭University Hospital Basel, Basel, Switzerland